PROVENTION BIO INC
BiotechPROVENTION BIO INC is a biotechnology company focused on Metabolic, Immunology, Infectious Disease.
FDA Novel Drug Designations
(2022)See 1 novel approval →
PROVENTION BIO INC at a Glance
- Strong track record with 100% execution quality across 5 trials
- Fast trial execution (12 months median completion)
PROVENTION BIO INC's Key Drugs
PROVENTION BIO INC's core commercial portfolio centers on TZIELD, spanning Metabolic and Immunology — its most strategically important drugs approved in the last 15 years.
PROVENTION BIO INC's Recent FDA Approvals
New NDA/BLA approvals for PROVENTION BIO INC over the last two years — novel drugs only, excluding generics and label supplements.
PROVENTION BIO INC's Therapeutic Areas
PROVENTION BIO INC's approved drugs and pipeline span 4 therapeutic areas, led by Metabolic and Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PROVENTION BIO INC's Top Competitors
PROVENTION BIO INC's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, ASTELLAS, and GSK. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PROVENTION BIO INC Pipeline Snapshot
PROVENTION BIO INC has 5 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 1 Phase 2 and 3 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TZIELD leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 1/1 completed
- • Speed: 12 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2022-11-17
- Latest
- 2026-06-12
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges